The administration of cannabis oil extracts high in cannabidiol reduces seizure frequency in children with intractable epilepsy, according to clinical data published online ahead of print in the journal Seizure.
Israeli researchers retrospectively evaluated the effects of CBD oil in a multicenter cohort of 74 patients with intractable epilepsy. Participants in the trial were resistant to conventional epilepsy treatment and were treated with CBD extracts for a period of at least three months. Extracts in the study were provided by a pair of Israeli-licensed growers and were standardized to possess a CBD to THC ratio of 20 to 1.
Investigators reported: “CBD treatment yielded a significant positive effect on seizure load. Most of the children (89 percent) reported reduction in seizure frequency. … In addition, we observed improvement in behavior and alertness, language, communication, motor skills and sleep.”
They concluded, “The results of this multicenter study on CBD treatment for intractable epilepsy in a population of children and adolescents are highly promising. Further prospective, well-designed clinical trials using enriched CBD medical cannabis are warranted.”
In 2013, the United States Food and Drug Administration granted orphan drug status to imported, pharmaceutically standardized CBD (aka Epidiolex) extracts for use in experimental pediatric treatment. Open-label safety trial data published online in December 2015 in the journal Lancet Neurology reported a median reduction in seizures in adolescent patient treated with Epidiolex that approached 40 percent. Authors concluded, “Our findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy.”
An abstract of the study, “CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience,” appears online here.
Electronically driven vaporizers deliver cannabinoids in a relatively safe and reliable manner, according to data published in the journal PLOS ONE.
Swiss investigators evaluated the ability of various types of vaporizer technologies to safely and effectively release THC and CBD (cannabidiol) in vapor. Researchers reported that electronically driven devices, which allow for precise temperature control, were able to provide for relatively safe and uniform dosing. By contrast, gas-powered devices performed in a more unreliable manner and “cannot be recommended for therapeutic purposes.”
Authors concluded, “[T]he four electrically-driven and temperature-controlled vaporizers investigated in this study efficiently decarboxylate acidic cannabinoids and release reliably the corresponding neutral cannabinoids into the vapor. Therefore, they can be considered as a promising application mode for the safe and efficient administration of medicinal cannabis and cannabinoids.”
Vaporizer technology seeks to heat marijuana to a point where cannabinoid vapors form, but below the point of combustion. In clinical trials, investigators have concluded that vaporization “does not result in exposure to combustion gases” and produces higher plasma concentrations of THC compared to smoked cannabis.
The full text of the study, Medicinal Cannabis: “In vitro validation of vaporizers for the smoke-free inhalation of cannabis,” appears online here.
The administration of liquid cannabis extracts containing THC is associated with the mitigation of various symptoms of Alzheimer’s-related agitation and dementia, according to observational trial data published online ahead of print in The Journal of Alzheimer’s Disease.
Israeli investigators assessed the use of cannabis oil as an adjunct pharmacotherapy treatment in ten Alzheimer’s disease patients over a period of several weeks. Researchers reported that drug administration was associated with a significant reduction in patients’ symptom severity scores. Specifically, cannabis oil ingestion corresponded with decreased levels of aggression, irritability, apathy, and delusions.
Investigators concluded, “Adding medical cannabis oil to Alzheimer’s disease patients pharmacotherapy is safe and a promising treatment option.”
The administration of dronabinol (oral synthetic THC in pill form) has previously been reported to reduce Alzheimer’s-induced agitation and improve weight gain, while preclinical studies have theorized that cannabinoids may be neuroprotective against the onset of the disease.
An abstract of the study, “Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An open label, add-on, pilot study,” appears online here.
Investigators at the University of California, Los Angeles and the University of Minnesota evaluated whether marijuana use was associated with changes in intellectual performance in two longitudinal cohorts of adolescent twins. Participants were assessed for intelligence at ages 9 to 12, before marijuana involvement, and again at ages 17 to 20.
Researchers reported no dose-response relationship between cannabis use and IQ decline. They also found no significant differences in performance among marijuana using subjects when compared to their non-using twins.
Investigators concluded: “In the largest longitudinal examination of marijuana use and IQ change, … we find little evidence to suggest that adolescent marijuana use has a direct effect on intellectual decline. … [T]he lack of a dose–response relationship, and an absence of meaningful differences between discordant siblings lead us to conclude that the deficits observed in marijuana users are attributable to confounding factors that influence both substance initiation and IQ rather than a neurotoxic effect of marijuana.”
The findings follow the publication of a separate longitudinal study in the Journal of Pharmacology which concluded that cumulative adolescent marijuana use is not associated with lower IQ or poorer educational performance once adjustments are made for potential confounders, specifically cigarette smoking.
An abstract of the study, “Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies,” is online here.
Researchers from Texas A&M University and the University of Florida, Gainesville evaluated drug use patterns from a nationally representative sample of 2,835 12th graders.
Authors found that youth use of alcohol most often preceded the use of tobacco or marijuana. They also reported subjects’ age of alcohol initiation is the strongest predictor of later polydrug use.
“Alcohol is the most commonly used substance, and the majority of polysubstance using respondents consumed alcohol prior to tobacco or marijuana initiation,” they reported. “Respondents initiating alcohol use in sixth grade reported significantly greater lifetime illicit substance use and more frequent illicit substance use than those initiating alcohol use in ninth grade or later.”
They concluded, “Our results … assert that the earlier one initiates alcohol use, the more likely that they will engage in future illicit substance use.”
The findings are inconsistent with recent claims made by several prominent lawmakers that cannabis is a ‘gateway’ to later substance abuse.
Studies conducted by the RAND Corporation and others have previously dismissed any alleged causal role of marijuana as a gateway to subsequent illicit drug abuse, finding, “There is no conclusive evidence that the drug effects of marijuana are causally linked to the subsequent abuse of other drugs.”
An abstract of the study, “Prioritizing Alcohol Prevention: Establishing Alcohol as the Gateway Drug and Linking Age of First Drink With Illicit Drug Use,” appears online here.